Firefly Neuroscience (NASDAQ:AIFF) Releases Earnings Results

Firefly Neuroscience (NASDAQ:AIFF) posted its quarterly earnings results on Tuesday. The company reported ($0.16) EPS for the quarter, Zacks reports. The company had revenue of $0.41 million for the quarter. Firefly Neuroscience had a negative net margin of 2,705.88% and a negative return on equity of 319.00%.

Firefly Neuroscience Trading Up 2.8%

NASDAQ AIFF opened at $2.24 on Thursday. Firefly Neuroscience has a 1-year low of $0.62 and a 1-year high of $4.51. The company has a 50 day moving average of $1.31 and a 200-day moving average of $1.66. The firm has a market cap of $31.84 million, a price-to-earnings ratio of -1.24 and a beta of 1.92.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Firefly Neuroscience in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC raised its position in shares of Firefly Neuroscience by 92.9% in the 2nd quarter. Geode Capital Management LLC now owns 120,604 shares of the company’s stock valued at $341,000 after acquiring an additional 58,067 shares during the period. Jane Street Group LLC bought a new stake in Firefly Neuroscience in the 4th quarter valued at $53,000. Finally, Vanguard Group Inc. grew its stake in shares of Firefly Neuroscience by 393.3% during the 3rd quarter. Vanguard Group Inc. now owns 503,071 shares of the company’s stock worth $1,464,000 after acquiring an additional 401,085 shares in the last quarter. 4.96% of the stock is currently owned by institutional investors and hedge funds.

About Firefly Neuroscience

Firefly Neuroscience is a clinical‐stage neurotechnology company focused on developing digital biomarkers and cognitive assessment tools for the early detection and monitoring of neurological disorders. The company’s platform combines mobile applications, sensor technology and advanced analytics to capture objective brain function data outside of traditional clinical settings. By providing real‐world cognitive and physiological measurements, Firefly aims to improve diagnosis, track disease progression and support therapeutic development.

The company’s flagship offering is a smartphone‐based cognitive assessment app that guides users through a series of interactive tasks designed to measure attention, memory, processing speed and executive function.